<- Go Home
Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Market Cap
$1.2B
Volume
1.8M
Cash and Equivalents
$41.8M
EBITDA
-$142.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$86.8M
Profit Margin
N/A
52 Week High
$7.00
52 Week Low
$3.35
Dividend
N/A
Price / Book Value
8.54
Price / Earnings
-8.35
Price / Tangible Book Value
9.27
Enterprise Value
$1.1B
Enterprise Value / EBITDA
-7.60
Operating Income
-$142.8M
Return on Equity
105.48%
Return on Assets
-50.15
Cash and Short Term Investments
$174.8M
Debt
$30.4M
Equity
$143.7M
Revenue
N/A
Unlevered FCF
-$57.6M
Sector
Biotechnology
Category
N/A